QUÉBEC CITY, Nov. 19, 2013 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ:
AEZS) (TSX: AEZ) (the "Company") today announced that it has commenced
an underwritten public offering of units (the "Offering"), consisting
of common shares and warrants to purchase common shares. The pricing
and number of Units as well as the exercise price and duration of the
warrants will be determined in the course of marketing.
Canaccord Genuity is acting as sole book-running manager for the
proposed Offering. The proposed Offering is subject to customary
conditions, including the approval of the Toronto Stock Exchange
("TSX") and The NASDAQ Stock Market ("NASDAQ"), and there can be no
assurance as to whether or when the proposed Offering may be completed,
or as to the actual size or terms of the Offering. The Company has no
intention of listing the warrants on the TSX or NASDAQ.
The Offering is being conducted pursuant to the Company's effective
shelf registration statement on Form F-10 filed with the U.S.
Securities and Exchange Commission (the "SEC"), its corresponding
Canadian base shelf prospectus and an exemption from the Autorité des marches financiers permitting the Company to offer common shares and warrants in the
United States. The proposed offering will be made only by means of a
preliminary prospectus supplement, a final prospectus supplement and
the accompanying short form base shelf prospectus. When available,
copies of the preliminary prospectus supplement, the final prospectus
supplement and the accompanying short form base shelf prospectus may be
obtained upon request by contacting Canaccord Genuity Inc., Attention:
Syndicate Department, 99 High Street, 12th Floor, Boston, Massachusetts 02110, or by telephone at (617) 371-3900.
Electronic copies of the preliminary prospectus supplement, the final
prospectus supplement and the accompanying short form base shelf
prospectus will also be available free of charge at www.sedar.com and www.sec.gov, respectively.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy the securities described herein, nor
shall there be any sale of these securities in any jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company engaged in
developing novel treatments in oncology and endocrinology. The
Company's pipeline encompasses compounds from drug discovery to
regulatory approval. For more information, visit www.aezsinc.com.
This press release contains forward-looking statements made pursuant to
the safe harbour provisions of the U.S. Securities Litigation Reform
Act of 1995. Forward-looking statements involve known and unknown risks
and uncertainties that could cause the Company's actual results to
differ materially from those in the forward-looking statements. Such
risks and uncertainties include, among others, the availability of
funds and resources to pursue R&D projects, the successful and timely
completion of clinical studies, the risk that safety and efficacy data
from any of our Phase 3 trials may not coincide with the data analyses
from previously reported Phase 1 and/or Phase 2 clinical trials, the
ability of the Company to take advantage of business opportunities in
the pharmaceutical industry, uncertainties related to the regulatory
process and general changes in economic conditions. Investors should
consult the Company's quarterly and annual filings with the Canadian
and U.S. securities commissions for additional information on risks and
uncertainties relating to forward-looking statements. Investors are
cautioned not to rely on these forward-looking statements. The Company
does not undertake to update these forward-looking statements. We
disclaim any obligation to update any such factors or to publicly
announce the result of any revisions to any of the forward-looking
statements contained herein to reflect future results, events or
developments, unless required to do so by a governmental authority or
by applicable law.
SOURCE: Aeterna Zentaris Inc.
For further information:
Ginette Beaudet Vallières
Investor Relations Coordinator
(418) 652-8525 ext. 265
Director of Communications
(418) 652-8525 ext. 406